FMT plus pembrolizumab for advanced lung cancer after prior treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial studies whether adding fecal microbiome transplant (FMT) to pembrolizumab can help people with advanced, PD-L1–positive non-small cell lung cancer that has returned or progressed after anti–PD-1/PD-L1 therapy. You may be asked to give new tumor tissue and undergo gut procedures, because the study aims to change gut bacteria to boost the immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV non-small cell lung cancer with PD-L1 at 1% or higher on a specific tumor test (IHC using an FDA-approved method).
- Your cancer progressed after at least 2 doses of an anti–PD-1/PD-L1 medicine (you may still qualify if progression happened soon after certain prior treatments).
- You have measurable disease on scans and you can provide a new tumor biopsy (from a spot not previously irradiated).
- Your brain (if involved) must be treated and stable, and you must not have leptomeningeal spread of cancer in the brain covering layers.
- You can safely undergo bowel prep plus repeated FMT treatments (endoscopy and pill form) and understand infection/allergy risks.
- You are well enough for treatment (ECOG performance status 0–1) and have adequate organ function; screening checks include hepatitis viruses and HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of fecal microbiota transplantation (FMT), immunotherapy, and chemotherapy as a first treatment for advanced non-small cell lung cancer that does not have a driver gene mutation. The goal is to see if adding FMT can help the immune system fight the cancer better.
This study tests whether giving a fecal microbiota transplant (a stool transplant from a healthy donor or someone who responded well to immunotherapy) together with the immunotherapy drug tislelizumab can help people with advanced or metastatic non-small cell lung cancer (NSCLC). It's for patients whose cancer grew after prior immunotherapy.
This trial tests if a fecal transplant from immunotherapy responders can help treat stage II-III non-small cell lung cancer patients who haven't had treatment yet.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.